2021

Artax Biopharma Announces First-in-Human Dosing for AX-158
16/12/2021

First-in-Human Dosing in Phase 1 Clinical Trial for AX-158, Company's First-in-Class Oral Immunomodulator to Treat T Cell-Mediated Diseases The Phase 1... Read More
Aleta Biotherapeutics Announces ALETA-001
13/12/2021

Aleta Biotherapeutics Announces ALETA-001 Poster Presentation at the 63rd American Society of Hematology (ASH) Annual Meeting Pre-clinical results demonstrate durable response... Read More
Vifor Pharma to acquire Sanifit
22/11/2021

Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology Vifor Pharma to acquire Sanifit, a clinical-stage cardio-renal biopharmaceutical... Read More
Highlight Therapeutics: Positive Phase 2b results in 2nd line melanoma
16/11/2021

Highlight Therapeutics presents a medical breakthrough at the SITC oncology congress, being the first time that a drug shows a positive... Read More
Aura Biosciences is trading on the Nasdaq Global Market
04/11/2021

Columbus Venture Partners Portfolio Company, Aura Biosciences, is trading on the Nasdaq Global Market Aura Biosciences (Cambridge, USA), whose founder is... Read More
Columbus VP creates a new company in Bizkaia for synthetic DNA production: Syngoi Technologies
06/10/2021

Columbus Venture Partners creates a new company in Bizkaia for synthetic DNA production: Syngoi Technologies Madrid, 5 October 2021. Today Columbus... Read More
Fatro secures European authorization for rabbit vaccine with Algenex tech
28/09/2021

Fatro secures European authorization for rabbit vaccine with Algenex tech 24 Sep 2021 - Animal Health | Headline AnalysisProduct Approvals The European... Read More
Artax Biopharma Granted MHRA Clinical Trial Authorization for AX-158
26/07/2021

Artax Biopharma Granted MHRA Clinical Trial Authorization for AX-158 Cambridge, Mass., July 13, 2021 – Artax Biopharma, Inc., a biotechnology company... Read More
NeRRe Therapeutics raises £20 million in a Series B2 financing round
07/07/2021

NeRRe Therapeutics raises £20 million in a Series B2 financing round New funds to evaluate orvepitant as a treatment for the disabling... Read More
Bayer’s gene therapy CDMO Viralgen cuts ribbon on first phase of $142M
01/07/2021

Bayer's gene therapy CDMO Viralgen cuts ribbon on first phase of $142M viral vector expansion Jun 30, 2021 10:20am -Viralgen, the... Read More